A Trial of Lopinavir-Ritonavir in Covid-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Treatment Options for COVID-19-Related Guillain-Barré Syndrome: A Systematic Review of Literature.The neurologist · 2021
   Pooled it
2. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.Trials · 2021
   Article
3. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.European journal of clinical pharmacology · 2021
   Article
4. The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time.Frontiers in medicine · 2021
   Review
5. Potential Effects of Coronaviruses on the Liver: An Update.Frontiers in medicine · 2021
   Review
6. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.Journal of clinical medicine · 2020
   Review
7. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.Frontiers in immunology · 2020
   Review
8. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.Frontiers in oncology · 2020
   Article
9. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.Intervirology · 2020
   Review

Corrections and comments

• Commented on by
  A Trial of Lopinavir-Ritonavir in Covid-19. Reply.2020
• Comment on
  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.2020

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as